| Percentage of tumors with specific spectrum of mutation | No. of cases with TP53 mutation | TP53 mutation incidence | |||||||
| Missense | Nonsense | Frameshift | Splicing | Silent | Others | Null type* | |||
| The present study | 52% | 40% | 4% | 4% | 0% | 0% | 48% | 25 | 45% |
| Erber (GermanyOncogene 1998) | 88% | 5% | 5% | 5% | 5% | 41 | 47% | ||
| Alsner (DenmarkRadioTxOncol 2001) | 53% | 14% | 9% | 12% | 12% | 0% | 34% | 58 | 39% |
| Eriksen (Denmark, RadioTxOncol 2005) | 54% | 25% | 3% | 17% | 0% | 28% | 125 | 60% | |
| Peronne (Italy, JCO 2010) | 83% | 8% | 8% | 0% | 0% | 0% | 17% | 24 | 45% |
| IARC database (HNSCC) | 60% | 13% | 14% | 5% | 3% | 5% | 32% | 614 | 42% |
| IARC database (All primary sites) | 74% | 8% | 9% | 2% | 4% | 4% | 18% | 26597 | NR |